As expected, FcRH5 CAR-T cells launched significantly augmented production of IFN-γ and 6-h cytolysis towards patient-derived autologous primary myeloma cells compared with mock T cells (Fig. 2f, g), underscoring the appreciable anti-MM efficacy of FcRH5 CAR-T cells in the autologous settings ex vivo. Here, FCRL5 is linked to plasma cell myeloma.